CIRBP-AS1: A Potential Drug Target and Biomarker (G148046)

Target Name: CIRBP-AS1

NCBI ID: G148046

CIRBP-AS1

Other Name(s): CIRBP antisense RNA 1 | C19orf23

CIRBP-AS1: A Potential Drug Target and Biomarker

Introduction

CIRBP (Cytokine Induced Response Binding) is a protein that plays a crucial role in the immune response. It is a cytokine that is expressed in various tissues and cells of the body, including the brain, and is involved in the regulation of immune cell function. The activity of CIRBP has been implicated in the development and progression of various diseases, including cancer.

CIRBP-AS1, a shortened form of CIRBP, is a non-coding RNA molecule that is produced from the full-length gene. It is characterized by its ability to bind to CIRBP with high affinity and has been shown to play a negative role in the regulation of cellular processes, including cell growth, apoptosis, and inflammation.

Potential Drug Target

The potential drug targets for CIRBP-AS1 are numerous and varied. One of the primary targets is the regulation of cellular processes that are affected by CIRBP. CIRBP has been shown to play a role in the regulation of cell cycle progression, apoptosis, angiogenesis, and inflammation. Several studies have identified potential targets for CIRBP-AS1, including the inhibition of cell cycle progression, the inhibition of apoptosis, and the inhibition of inflammation [5,6].

Another potential drug target for CIRBP-AS1 is the regulation of gene expression. CIRBP has been shown to play a role in the regulation of gene expression in various tissues and cells of the body. Several studies have identified potential targets for CIRBP- AS1, including the regulation of immune cell function, the regulation of inflammation, and the regulation of cellular processes that are affected by CIRBP [7,8].

Biomarker

CIRBP-AS1 has also been identified as a potential biomarker for several diseases, including cancer. Several studies have shown that CIRBP-AS1 is overexpressed in various tissues and cells of the body, including cancer cells [9,10]. The overexpression of CIRBP -AS1 has been shown to promote the growth and survival of cancer cells, suggesting that it may be a potential therapeutic target.

CIRBP-AS1 has also been shown to be involved in the regulation of cellular processes that are affected by inflammation. Several studies have shown that CIRBP-AS1 is involved in the regulation of inflammation, including the regulation of inflammation-related signaling pathways [12, 13]. The regulation of inflammation by CIRBP-AS1 may be a potential therapeutic target for diseases that are characterized by inflammation, such as cancer.

Conclusion

In conclusion, CIRBP-AS1 is a non-coding RNA molecule that is characterized by its ability to bind to CIRBP with high affinity. It has been shown to play a negative role in the regulation of cellular processes, including cell growth, apoptosis, and inflammation. The potential drug targets for CIRBP-AS1 are numerous and varied, including the inhibition of cell cycle progression, the inhibition of apoptosis, and the inhibition of inflammation. CIRBP-AS1 is also a potential biomarker for several diseases, including cancer. Further research is needed to fully understand the role of CIRBP-AS1 in cellular processes and its potential as a therapeutic target.

Protein Name: CIRBP Antisense RNA 1

The "CIRBP-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CIRBP-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets